United Therapeutics Corporation (UTHR) : Krensavage Asset Management scooped up 51,803 additional shares in United Therapeutics Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 275,248 shares of United Therapeutics Corporation which is valued at $34,458,297.United Therapeutics Corporation makes up approximately 11.91% of Krensavage Asset Management’s portfolio.
Other Hedge Funds, Including , Janus Capital Management boosted its stake in UTHR in the latest quarter, The investment management firm added 1,933 additional shares and now holds a total of 13,312 shares of United Therapeutics Corporation which is valued at $1,666,529. Lockheed Martin Investment Management Co added UTHR to its portfolio by purchasing 25,400 company shares during the most recent quarter which is valued at $3,179,826. United Therapeutics Corporation makes up approx 0.30% of Lockheed Martin Investment Management Co’s portfolio.First Trust Advisors Lp reduced its stake in UTHR by selling 117,442 shares or 32.01% in the most recent quarter. The Hedge Fund company now holds 249,469 shares of UTHR which is valued at $31,250,982. United Therapeutics Corporation makes up approx 0.09% of First Trust Advisors Lp’s portfolio.Harel Insurance Investments Financial Services Ltd. reduced its stake in UTHR by selling 40 shares or 18.96% in the most recent quarter. The Hedge Fund company now holds 171 shares of UTHR which is valued at $21,351.
United Therapeutics Corporation opened for trading at $121.75 and hit $122.84 on the upside on Monday, eventually ending the session at $122.04, with a gain of 0.23% or 0.28 points. The heightened volatility saw the trading volume jump to 3,84,891 shares. Company has a market cap of $5,305 M.
On the company’s financial health, United Therapeutics Corporation reported $4.55 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $3.52. The company had revenue of $412.60 million for the quarter, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.
Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.